Enanta Pharmaceuticals (ENTA) Common Equity (2012 - 2026)

Enanta Pharmaceuticals' Common Equity history runs 15 years deep, the most recent figure standing at $116.6 million for Q1 2026.

• Quarterly Common Equity rose 24.64% year-over-year to $116.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.6 million (up 24.64% YoY) and the FY2025 annual result came in at $64.7 million, down 49.76% from the prior year.
• Common Equity was $116.6 million for Q1 2026 at Enanta Pharmaceuticals, down from $126.6 million in the prior quarter.
• Across five years, Common Equity topped out at $358.6 million in Q1 2022 and bottomed at $64.7 million in Q3 2025.
• A 5-year average of $192.4 million and a median of $166.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity plunged 49.76% — and 2026, when it advanced 24.64%.
• Enanta Pharmaceuticals' Common Equity stood at $300.8 million in 2022, then tumbled by 36.22% to $191.9 million in 2023, then tumbled by 41.73% to $111.8 million in 2024, then rose by 13.21% to $126.6 million in 2025, then decreased by 7.9% to $116.6 million in 2026.
• Business Quant data shows ENTA's Common Equity at $116.6 million in Q1 2026, $126.6 million in Q4 2025, and $64.7 million in Q3 2025.